NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
This publication is provided for historical reference only and the information may be out of date.
Screening for Hepatitis C Virus Infection in Adults
Comparative Effectiveness Reviews, No. 69
Investigators: Roger Chou, MD, Erika Barth Cottrell, PhD, MPP, Ngoc Wasson, MPH, Basmah Rahman, MPH, and Jeanne-Marie Guise, MD, MPH.
Author Information and AffiliationsStructured Abstract
Objectives:
Many patients with chronic hepatitis C virus (HCV) infection are unaware of their status. Screening could identify patients at earlier stages of disease, when interventions might be effective in improving clinical outcomes or reducing transmission risk. The purpose of this report is to systematically review the evidence on screening for HCV infection in asymptomatic adults without known liver enzyme abnormalities, including pregnant women. This review focuses on research gaps identified in the 2004 United States Preventive Services Task Force (USPSTF) review and new studies published since that review, and it reviews evidence on prenatal HCV screening not included in the 2004 USPSTF review. This report examines both direct evidence on the effects of screening for HCV infection compared to no screening on clinical outcomes, as well as the indirect chain of evidence (diagnosis, workup, and treatment) needed to understand effects of screening on clinical outcomes. Treatments evaluated included immunizations, counseling, and interventions to potentially reduce risk of mother-to-child transmission. To complement this review of screening for HCV, the Agency for Healthcare Research and Quality (AHRQ) commissioned a separate review on effectiveness of antiviral treatments.
Data sources:
Articles were identified from searches (from 1947 to May 2012) of the Cochrane Database of Systematic Reviews, the Cochrane Central Register of Controlled Trials, EBM Reviews, and Ovid MEDLINE®. The searches were supplemented by reviewing reference lists and searching clinical trial registries.
Review methods:
We used predefined criteria to determine study eligibility. We selected randomized trials and observational studies that evaluated effects of screening, counseling interventions, and immunizations on clinical and intermediate outcomes. We also selected studies that evaluated effects of labor and delivery practices and breastfeeding on mother-to-child transmission of HCV infection. We selected studies that evaluated the diagnostic accuracy of noninvasive tests compared to liver biopsy for diagnosing fibrosis or cirrhosis in patients with chronic HCV infection. The quality of included studies was assessed, data were extracted, and results were summarized.
Results:
Of the 10,786 citations identified at the title and abstract level, we screened and reviewed 808 full-length articles. A total of 182 studies were included. There was no direct evidence on clinical benefits associated with screening compared with no screening (or comparing different screening approaches) in nonpregnant or pregnant adults. Retrospective studies found that screening strategies targeting multiple risk factors were associated with sensitivities of over 90 percent and numbers needed to screen to identify one case of HCV infection of less than 20. Narrowly targeted screening strategies based on history of intravenous drug use were associated with numbers needed to screen of less than two, but missed up to two-thirds of infected people. Data on harms of screening (such as labeling and anxiety) were sparse. Compared with liver biopsy, a number of indices based on panels of blood tests were associated with a median area under the receiver operating characteristic curve (AUROC) of 0.75 to 0.86 for diagnosing fibrosis and a median AUROC of 0.80 to 0.91 for diagnosing cirrhosis, but there was insufficient evidence to determine clinical outcomes associated with strategies incorporating noninvasive tests for evaluating patients with HCV infection. Limited evidence suggested that knowledge of HCV status and counseling interventions may reduce alcohol use and risky injection drug use behaviors, but more evidence is needed to demonstrate long-term sustainability and to understand effects on clinical outcomes and transmission risk. In pregnant women, cohort studies found no clear association between mode of delivery and risk of vertical transmission of HCV infection and consistently found no association between breastfeeding and transmission risk. Evidence on the association between other labor and delivery management practices and risk of vertical transmission of HCV infection was sparse, but suggested that prolonged rupture of membranes is associated with increased risk.
Conclusions:
Although screening tests can accurately identify adults with chronic HCV infection, targeted screening strategies based on the presence of risk factors miss some patients with HCV infection. As a result, more research is needed to understand the effects of different screening strategies on clinical outcomes. Evidence on effects of knowledge of HCV status and counseling and immunizations on clinical and intermediate outcomes in patients diagnosed with HCV infection remains sparse and more research is needed to understand effective interventions for preventing vertical transmission. A complete assessment of benefits and harms of screening requires consideration of the effectiveness of antiviral regimens, which are the subject of a complementary review.
Contents
- Preface
- Acknowledgments
- Key Informants
- Technical Expert Panel
- Peer Reviewers
- Executive Summary
- Introduction
- Methods
- Results
- Key Question 1a Does screening for HCV infection in asymptomatic nonpregnant adults reduce mortality and morbidity due to HCV, affect quality of life, or reduce transmission of HCV?
- Key Question 1b Does screening for HCV infection during pregnancy reduce vertical transmission of HCV or improve mortality or morbidity for the mother or child?
- Key Question 2a What is the effectiveness of different risk-or prevalence-based methods for screening for HCV infection on clinical outcomes?
- Key Question 2b What is the sensitivity and number needed to screen to identify one case of HCV infection of different risk- or prevalence-based methods for screening for HCV infection?
- Key Question 3 What are the harms associated with screening for HCV infection, including adverse effects such as anxiety, labeling, and impact on relationships?
- Key Question 4a What is the comparative effectiveness and comparative diagnostic accuracy of various tests and strategies for the workup to guide treatment decisions in patients who are HCV positive?
- Key Question 4b What proportion of patients with screen-detected HCV infection receives treatment?
- Key Question 5 What are the harms associated with the workup for guiding treatment decisions?
- Key Question 6a How effective is counseling or immunization of patients with HCV infection at improving health outcomes or reducing the spread of HCV?
- Key Question 6b Does becoming aware of positive HCV infection status decrease high-risk behaviors?
- Key Question 6c How effective is counseling and immunization of patients with HCV infection at improving intermediate outcomes, including change in high-risk behaviors?
- Key Question 7 Do any interventions decrease or increase the vertical transmission of HCV during delivery or in the perinatal period?
- Discussion
- References
- Abbreviations and Acronyms
- Appendix A Exact Search Strategy
- Appendix B Hepatitis C Screening: Inclusion Criteria by Key Question
- Appendix C Included Studies
- Appendix D Excluded Studies
- Appendix E Quality Assessment Methods
- Appendix F Overall Strength of Evidence: Summary of Grading Domains
- Appendix G Evidence Tables and Overall Quality Ratings
Prepared for: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services1, Contract No. 290-2007-10057-I, Prepared by: Oregon Evidence-based Practice Center, Portland, OR
Suggested citation:
Chou R, Cottrell EB, Wasson N, Rahman B, Guise J-M. Screening for Hepatitis C Virus Infection in Adults. Comparative Effectiveness Review No. 69. (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-2007-10057-I.) AHRQ Publication No. 12(13)-EHC090-EF. Rockville, MD: Agency for Healthcare Research and Quality. November 2012. www.effectivehealthcare.ahrq.gov/reports/final.cfm.
This report is based on research conducted by the Oregon Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2007-10057-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.
The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.
This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.
None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.
- 1
540 Gaither Road, Rockville, MD 20850; www
.ahrq.gov
- Review Screening for Hepatitis C Virus Infection[ 2004]Review Screening for Hepatitis C Virus InfectionChou R, Clark E, Helfand M. 2004 Mar
- Review Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force[ 2016]Review Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: A Systematic Evidence Review for the U.S. Preventive Services Task ForceLozano P, Henrikson NB, Dunn J, Morrison CC, Nguyen M, Blasi PR, Anderson ML, Whitlock E. 2016 Aug
- Review Screening for HIV: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation[ 2012]Review Screening for HIV: Systematic Review to Update the U.S. Preventive Services Task Force RecommendationChou R, Selph S, Dana T, Bougatsos C, Zakher B, Blazina I, Korthuis PT. 2012 Nov
- Review Lipid Screening in Childhood for Detection of Multifactorial Dyslipidemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force[ 2016]Review Lipid Screening in Childhood for Detection of Multifactorial Dyslipidemia: A Systematic Evidence Review for the U.S. Preventive Services Task ForceLozano P, Henrikson NB, Morrison CC, Dunn J, Nguyen M, Blasi P, Whitlock EP. 2016 Aug
- Review Screening for hepatitis C virus infection in adults: a systematic review for the U.S. Preventive Services Task Force.[Ann Intern Med. 2013]Review Screening for hepatitis C virus infection in adults: a systematic review for the U.S. Preventive Services Task Force.Chou R, Cottrell EB, Wasson N, Rahman B, Guise JM. Ann Intern Med. 2013 Jan 15; 158(2):101-8.
- Screening for Hepatitis C Virus Infection in AdultsScreening for Hepatitis C Virus Infection in Adults
Your browsing activity is empty.
Activity recording is turned off.
See more...